Having trouble accessing articles? Reset your cache.

Arcellx debuts with $85M, tech for adapting CAR Ts

Arcellx is leveraging its CAR T experts and $85M B round to bring the cells to new indications

Arcellx emerged from stealth with over $85 million in series B funding and a team of CAR T veterans to develop the latest iteration of a CAR T adaptor platform that balances safety and efficacy by carefully tuning adaptor protein half life. The team believes its platform can treat refractory cancers and move into non-oncology indications.

The series B round was led by new investors Aju IB Investment and Quan Capital.

The CAR T adaptor concept involves creating T cells with CARs that target an intermediary adaptor protein designed to bind a tumor

Read the full 914 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers